Evidence map›Paper›PMID 40090695›Full record

ArticleBMJ global health2025

Longitudinal study on quality of life following cervical cancer treatment in Botswana.

Surbhi Grover, Rohini K Bhatia, Salman Khan, Paseka Tladi, Lesego Gabaitiri, Memory Bvochora-Nsingo, Sebathu Chiyapo, Dawn Balang, Shalini Vinod, Mark N Polizzotto and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Surbhi GroverDepartment of Radiation Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania, USA Surbhi.Grover@pennmedicine.upenn.edu.
Rohini K BhatiaDepartment of Radiation Oncology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Salman KhanDepartment of Radiation Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID http://orcid.org/0009-0007-9209-6810
Paseka TladiDepartment of Mathematics and Statistical Sciences, Botswana International University of Science and Technology, Palapye, Botswana.
Lesego GabaitiriDepartment of Mathematics and Statistical Sciences, Botswana International University of Science and Technology, Palapye, Botswana.
Memory Bvochora-NsingoDepartment of Oncology, Gaborone Private Hospital, Gaborone, Botswana.
Sebathu ChiyapoDepartment of Oncology, Gaborone Private Hospital, Gaborone, Botswana.
Dawn BalangDepartment of Oncology, Gaborone Private Hospital, Gaborone, Botswana.
Shalini VinodUniversity of New South Wales, Sydney, New South Wales, Australia.
Mark N PolizzottoThe Australian National University College of Health and Medicine, Canberra, Canberra, Australia.
Natalie TaylorUniversity of New South Wales, Sydney, New South Wales, Australia.
Karen CanfellCanc Council NSW, Sydney, New South Wales, Australia.
Nicola ZetolaBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Doreen Ramogola-MasireDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of Botswana, Gaborone, South-East District, Botswana.
Lilie L LinDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Erle RobertsonDepartment of Otorhinolaryngology-Head and Neck Surgery, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Katharine A RendleFamily Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID http://orcid.org/0000-0002-7761-8728

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Shared Resources CoreU54CA190158 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2014 to 2023
$4.2M
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrenceK08CA230170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GROVER, SURBHI · 2019 to 2023
$1.4M
NCI NIH HHS K08 CA230170NCI NIH HHS P30 CA016520NCI NIH HHS U54 CA190158
6 · The paper itself

Abstract

purposeThis study longitudinally assessed the quality of life (QoL) in patients who completed chemoradiation (CRT) for cervical cancer in Botswana and compared the QoL for those living with and without HIV infection.

methodsPatients with cervical cancer recommended for curative CRT were enrolled from August 2016 to February 2020. The European Organisation for Research and Treatment of Cancer Core Quality-of-Life (QLQ-C30) and cervical cancer-specific (QLQ-Cx24) questionnaires, translated into Setswana, were used to assess the QoL of patients prior to treatment (baseline), at the end of treatment (EOT) and in 3 month intervals post-treatment for 2 years, and statistical analyses were performed.

resultsA total of 294 women (median age: 46 years) were enrolled and followed up for an average of 16.4 months. Of women with recorded staging, most had FIGO stage III/IV disease (64.4%). Women living with HIV (WLWH; 74.1%) presented at earlier ages than those without HIV (44.8 years vs 54.7 years, p<0.001). The QoL for all domains did not differ by HIV status at baseline, EOT or 24 month follow-up. Per QLQ-C30, the mean global health status score (72.21 vs 78.37; p<0.01) and the symptom (12.70 vs 7.63; p=0.04) and functional scales (88.34 vs 91.85; p<0.01) improved significantly from the EOT to the 24 month follow-up for all patients; however, using the QLQ-Cx24 survey, no significant differences in the symptom burden (12.53 vs 13.67; p=0.6) or functional status (91.23 vs 89.90; p=0.53) were found between these two time points.

conclusionThe QoL increased significantly for all patients undergoing CRT, underscoring the value of pursuing curative CRT, regardless of the HIV status.

Indexed as

ChemoradiotherapyQuality of LifeUterine Cervical NeoplasmsAdultAgedBotswanaFemaleHIV InfectionsHumansLongitudinal StudiesMiddle AgedSurveys and QuestionnairesCancerHIV

Identifiers

PMID40090695
PMCPMC11911664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.